Latest News and Press Releases

The submission is based on results from the Phase 3 AMPLITUDE study evaluating niraparib in combination with abiraterone acetate plus prednisone or prednisolone compared to a current standard of care,...

L’ITC ha confrontato tutti i dati di Fase 3 pubblicati relativi a questi trattamenti sfruttando i risultati longitudinali, i quali rafforzano l’importanza di un controllo costante e sostenuto della...

The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control in managing a chronic...

En cas d’autorisation, le daratumumab deviendra la première option thérapeutique autorisée pour les patients atteints d’un myélome multiple indolent et présentant un risque élevé de développer un...

En attendant la décision finale de la Commission européenne, le régime offre une nouvelle norme de soins pour les patients éligibles atteints d’LMC1,2 L’avis favorable confirme les résultats de...

Die Therapie, die erst noch durch die Europäische Kommission abschließend genehmigt werden muss, bietet das Potenzial, einen neuen Versorgungsstandard für geeignete MCL-Patienten zu schaffen.1,2 ...

The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control in managing a chronic...

Pending the European Commission final decision, regimen offers a new standard of care for eligible MCL patients1,2Positive opinion reinforces Phase 3 TRIANGLE study results by the European MCL...

If approved, daratumumab will be the first authorised treatment option for patients with smouldering multiple myeloma at high-risk of developing multiple myeloma, offering the potential for disease...

Die Ergebnisse der Phase II Studie RedirecTT-1 zeigen eine starke Reaktion mit einer Gesamtansprechrate von 78.9 Prozent durch die doppelte Zielgerichtete Therapie von GPRC5D und BCMA1  ...